Clinical Research
Filter News
Found 129,748 articles
-
Biopharma and life sciences companies and organizations from across the globe provide updates on their businesses and pipelines.
-
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06
9/16/2021
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. today announced positive interim results from the pivotal study “JUPITER-06” (NCT03829969), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as a first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).
-
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
9/16/2021
Agenus today presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021 in an abstract titled Balstilimab
-
Ventegra Partners with Scipher Medicine For Patient-Centric Approach To Improve Outcomes and Lower Costs for Rheumatoid Arthritis Care
9/16/2021
Scipher Medicine today announced a partnership with Ventegra, Inc., a new class-of-trade Medical Benefits Manager that uses innovative programs and products to ensure appropriate use of prescription drugs while lowering clients' costs.
-
Codex Beauty Labs, Leading Biotech Skincare Brand, Granted U.S. Patents for New Anti-Aging Line, Antü®
9/16/2021
Leading biotech beauty brand, Codex Beauty Labs , has been granted two U.S. patents related to its newest skincare line, Antü®.
-
54gene Closes $25M Series B to Advance Global Drug Discovery Capabilities
9/16/2021
54gene , the health technology company advancing African genomics research for improved global health outcomes, has secured $25M in a Series B round, led by Cathay AfricInvest Innovation Fund.
-
Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
9/16/2021
Data highlight the importance of utilizing genomic and proteomic testing for treatment guidance
-
Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
9/16/2021
Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases
-
Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole
9/16/2021
Derm-Biome Pharmaceuticals, Inc is pleased to announce that two of its topical drugs produced significant inhibitory effects in a well-established mouse model of atopic dermatitis (AD). AD is a chronic inflammatory skin disease with significant unmet need that is often linked to depression and a decreased quality of life.
-
Gynesonics Announces FDA Clearance of Next Generation Sonata System
9/16/2021
The Only Transcervical, Incisionless System for Radiofrequency Ablation of Fibroids Provides New Benefits through Features Such as Increased Range of Ablation Sizes, a New User Interface, and Validation of Additional Low Temperature Hospital Reprocessing Systems
-
New Studies Prove Direct Link Between MedWise® and Better Health Outcomes Including Reduced Healthcare Costs
9/16/2021
Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, today announced the results of a three-part clinical study that further demonstrates the strong associations between a high MedWise Risk Score™ and poor health outcomes.
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY Receives Full Health Canada Approval for Individuals 12 Years and Older
9/16/2021
Pfizer Canada ULC and BioNTech SE today announced that Health Canada has granted full approval (Notice of Compliance or NOC) for COMIRNATY® to prevent COVID-19 in individuals 12 years of age and older.
-
Qardio Announces the First Remote Patient Monitoring System to Include a Cardiac Monitoring Service in a Single, Intuitive Platform
9/16/2021
Qardio, Inc. announced today the launch of the first ever fully remote end-to-end RPM service to include cardiac arrhythmia analysis.
-
Fairjourney Biologics Announces THE ANTIBODY SERIES 2022
9/16/2021
FairJourney Biologics S.A., leader in the discovery and optimization of antibodies, today announced, after the overwhelming success of the 2021 ANTIBODY SERIES conference, planning for a larger scale 2022 ANTIBODY SERIES are underway.
-
Moderna Announces Health Canada Approves its COVID-19 Vaccine
9/16/2021
Moderna, Inc. today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine), which has been known as COVID-19 Vaccine Moderna, for active immunization to prevent COVID-19 in individuals 12 years of age and older.
-
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
9/16/2021
- Validated clinical pharmacology and positive psoriasis proof-of-concept clinical study with synthetic hypericin sets stage for pipeline expansion
-
Viemed Healthcare Announces Second Published Non-Invasive Ventilation Study
9/16/2021
Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX: VMD.TO), a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, announced another published non-invasive ventilation study led by Dr. William Frazier, Viemed’s Chief Medical Officer.
-
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
9/16/2021
ARCA biopharma, Inc. today announced that the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.
-
Pear Therapeutics Announces Publication of Real-World Data Showing Improved Clinical Outcomes with a Subsequent Prescription of reSET-O® for Patients with Opioid Use Disorder
9/16/2021
Sept. 16, 2021 12:35 UTC reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD)
-
Bantam Pharmaceutical Completes $25 Million Seed Funding to Finalize Preclinical Development and Prepare for First in Humans Trials
9/16/2021
Bantam Pharmaceutical today announced that it has completed a $25 million Seed Funding to finalize its ongoing IND-enabling activities for its lead program, BTM-3566, and consummate preparations for first in human clinical trials.